




Evolving reversible iMmunocapture by membrane sensing peptides: towARds scalable extracellular VEsicLes isolation

Extracellular vesicles (EVs) are cell-derived membranous structures found in all biological fluids that act as signalling vehicles in both physiological or pathological mechanisms. Accordingly, a flourishing of interest in EV research is constantly advancing towards their exploitation in precision healthcare, with particular focus on **Regenerative Medicine** and **Liquid biopsy**.



MARVEL will introduce an alternative class of affinity ligands (MSP) and (SPP) towards a modular and versatile platform for scalable EV isolation possibly generating an entire new products pipeline

MARVEL mission is to combine and implement reversible capturing and peptide science, towards the first and best performing ever affinity-based technology for scalable small EV (<200nm) isolation. The modularity in scaling-up of the novel protocols and kits will be demonstrated in relevant environments for therapeutic and diagnostics use of EVs.

Start date: 01/11/2020 - End date: 31/10/2022
Project budget: € 1.8 M
H2020 Research and Innovation Action
Grant Agreement: 951768
Call: H2020-EIC-FETPROACT-2019
Topic: FETPROACT-EIC-06-2019
EIC Transition to Innovation Activities
Contact: marina.cretich@cnr.it; l.debartolo@itm.cnr.it



This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No. 951768.

Partners



Associated Institute of the University of Zurich



University of Zurich UZH



UniSR
Università Vita-Salute San Raffaele